Study guide
12.1 Acute Kidney Injury & Renal Replacement Therapy
Certified Nutrition Support Clinician CNSC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Nutrition Screening, Dietary Evaluation & Energy Requirements
1.1 Nutrition Screening & Validated Risk Tools 1.2 Dietary History & Nutrient Intake Assessment 1.3 Energy Expenditure Estimation & Indirect Calorimetry
2 Chapter 2: Macronutrients, Micronutrients & Fluid Management
2.1 Protein Requirements & Nitrogen Balance 2.2 Fluid Requirements & Electrolyte Homeostasis 2.3 Essential Vitamins & Trace Elements
3 Chapter 3: Anthropometrics, Physical Exam & Malnutrition Consensus
3.1 Anthropometric Assessment & Body Composition 3.2 Nutrition-Focused Physical Examination (NFPE) 3.3 AND/ASPEN & GLIM Malnutrition Criteria
4 Chapter 4: Pediatric & Specialized Nutrition Assessment
4.1 Pediatric & Neonatal Nutrition Assessment 4.2 Biochemical Assessment, Visceral Proteins & Inflammation
5 Chapter 5: Enteral Nutrition Access & Tube Management
5.1 Enteral Access Modalities & Route Selection 5.2 Tube Placement Verification & Stoma Site Care
6 Chapter 6: Enteral Formulation, Regimen Design & Administration
6.1 Enteral Formula Classification & Selection 6.2 Enteral Delivery Methods & Infusion Schedules 6.3 Enteral Fluid Management & Free Water Requirements
7 Chapter 7: Enteral Complications & Medication Administration
7.1 Enteral Gastrointestinal Complications 7.2 Enteral Metabolic, Mechanical & Pulmonary Complications 7.3 Drug-Nutrient Interactions & Enteral Medication Delivery
8 Chapter 8: Parenteral Nutrition Indications, Access & Formulation Design
8.1 Parenteral Nutrition Indications & Venous Access Routes 8.2 Peripheral Parenteral Nutrition (PPN) Parameters 8.3 Central PN Macronutrient Formulation
9 Chapter 9: Parenteral Additives, Compounding & Physical Stability
9.1 Parenteral Electrolytes, Trace Elements & Vitamins 9.2 Calcium-Phosphate Solubility & Precipitation Risks 9.3 Physical Stability, Total Nutrient Admixtures & Filtration
10 Chapter 10: Parenteral Complications, CLABSI & Organ Toxicities
10.1 Central Line-Associated Bloodstream Infections & Mechanical Risks 10.2 Refeeding Syndrome Pathophysiology & Prevention 10.3 Parenteral Nutrition-Associated Liver Disease & Metabolic Bone Disease
11 Chapter 11: Critical Care, Obesity & Pulmonary Nutrition Support
11.1 Critical Illness, Sepsis & Trauma Nutrition 11.2 Nutrition Support in Obesity & Hypocaloric Feeding 11.3 Pulmonary Failure & Mechanical Ventilation 11.4 Nutrition Support Care Plans, Goals & Therapy Reassessment
12 Chapter 12: Organ Failure: Renal, Hepatic & Gastrointestinal Support
12.1 Acute Kidney Injury & Renal Replacement Therapy 12.2 Cirrhosis, Hepatic Encephalopathy & Acute Pancreatitis 12.3 Short Bowel Syndrome & Intestinal Failure
13 Chapter 13: Oncology, Surgical Care & Intestinal Failure
13.1 Oncology Nutrition & Cancer Cachexia 13.2 Perioperative Nutrition & Enhanced Recovery After Surgery (ERAS) 13.3 Enterocutaneous Fistulas & Severe Malabsorption
14 Chapter 14: Process Management, Compounding Safety & Home Nutrition Support
14.1 PN Order Verification, Compounding Safety & USP Standards 14.2 Home Nutrition Support (HNS) & Care Transitions 14.3 Nutrition Support Policies, Product Shortages & Patient Education
15 Chapter 15: Professional Practice, Ethics & Interdisciplinary Care
15.1 Ethical Principles & Withholding/Withdrawing Artificial Nutrition 15.2 The Interdisciplinary Nutrition Support Team 15.3 Quality Improvement, Malnutrition Documentation & Clinical Standards 15.4 Critical Appraisal of Nutrition Research & Evidence
12.1 Acute Kidney Injury & Renal Replacement Therapy
Key Takeaways Explain This Topic AI
In non-dialyzed acute kidney injury (AKI), protein prescriptions must support metabolic recovery (0.8–1.0 g/kg/day for non-catabolic states, 1.2–1.5 g/kg/day for catabolic illness); severe protein restriction (<0.6 g/kg/day) is obsolete and contraindicated in acute illness.
Intermittent hemodialysis (IHD) clears 10 to 12 g of free amino acids per treatment session, requiring a daily dietary protein target of 1.2 to 1.5 g/kg/day alongside strict interdialytic fluid and electrolyte restrictions.
Continuous renal replacement therapy (CRRT) extracts 10 to 15+ g of amino acids into effluent daily, requiring elevated protein delivery of 1.5 to 2.5 g/kg/day to achieve nitrogen equilibrium while permitting liberal fluid administration.
Non-nutritional caloric delivery during CRRT—specifically regional citrate anticoagulation (yielding 3.0 kcal/g or ~0.59 kcal/mmol) and dextrose absorption from dialysate/replacement solutions—delivers 200 to 800+ kcal/day.
Failure to quantify and deduct non-nutritional citrate and dialysate glucose calories from the total nutrition prescription induces overfeeding, severe hyperglycemia, elevated carbon dioxide production, and delayed ventilator weaning.
Last updated: October 2026
12.1 Acute Kidney Injury & Renal Replacement Therapy
Clinical Core: Acute kidney injury (AKI) is a hypercatabolic, pro-inflammatory syndrome characterized by the acute accumulation of nitrogenous waste, fluid overload, and profound electrolyte derangements. Nutrition support must never prioritize blood urea nitrogen (BUN) control over patient protein status. Severe protein restriction ( < 0.6 g/kg/day < 0.6\text{ g/kg/day} < 0.6 g/kg/day ) is obsolete and dangerous in acute illness. Protein prescriptions must match the specific renal replacement modality, scaling from 1.2 to 1.5 g/kg/day 1.2\text{ to } 1.5\text{ g/kg/day} 1.2 to 1.5 g/kg/day in intermittent hemodialysis up to 2.5 g/kg/day 2.5\text{ g/kg/day} 2.5 g/kg/day in continuous renal replacement therapy (CRRT) to offset substantial effluent amino acid washout. Furthermore, clinicians must quantify non-nutritional energy from regional citrate anticoagulation ( 3.0 kcal/g 3.0\text{ kcal/g} 3.0 kcal/g ) and dialysate glucose absorption to avoid iatrogenic overfeeding.
Metabolic Alterations & Catabolism in Acute Kidney Injury
Acute kidney injury (AKI) rarely presents as an isolated organ failure in clinical practice; it most commonly emerges in the setting of sepsis, major trauma, cardiopulmonary bypass, or multi-organ dysfunction syndrome (MODS). The metabolic milieu of AKI is distinct from chronic kidney disease (CKD):
Profound Proteolysis & Hypercatabolism: Systemic inflammation, metabolic acidosis, insulin resistance, and counter-regulatory hormones (cortisol, glucagon, epinephrine) accelerate skeletal muscle proteolysis. Muscle protein breakdown outpaces protein synthesis, generating excessive circulating amino acids that undergo hepatic deamination into urea.
Uremic Toxicity & Insulin Resistance: Elevated circulating uremic toxins impair peripheral glucose uptake, blunt insulin receptor signaling, and disrupt intracellular carbohydrate metabolism. Concurrently, renal gluconeogenesis (which normally accounts for 20% to 40% of endogenous glucose production) is impaired, and renal clearance of exogenous or endogenous insulin is decreased, predisposing patients to unpredictable glycemic swings.
Altered Lipid Homeostasis: Impaired renal clearance and downregulation of peripheral lipoprotein lipase reduce triglyceride hydrolysis, resulting in delayed clearance of intravenous lipid emulsions and hypertriglyceridemia.
Acid-Base and Solute Disequilibrium: Loss of nephron mass eliminates the primary route for non-volatile acid excretion (titratable acid and ammonium), leading to systemic metabolic acidosis. Metabolic acidosis directly activates the ubiquitin-proteasome pathway and branched-chain ketoacid dehydrogenase, further driving muscle breakdown.
Nutritional Prescriptions Across Renal Modalities
Nutritional requirements in renal disease are dictated primarily by the degree of metabolic stress and the modality of renal replacement therapy (RRT), rather than by serum BUN or creatinine alone. +-----------------------------------------------------------------------------------------+
- | RENAL REPLACEMENT MODALITY & PROTEIN SPECTRUM |
- +-----------------------------------------------------------------------------------------+
- | Modality | Clinical State | Protein Target | Fluid Allowance |
- | -------------------- | ------------------------ | ------------------- | --------------- |
- | Non-dialyzed AKI | Non-catabolic / Resolving| 0.8 - 1.0 g/kg/day | Output + 500 mL |
- | Non-dialyzed AKI | Catabolic / Critical Care| 1.2 - 1.5 g/kg/day | Strict balance |
- | Intermittent HD (IHD)| Intermittent Dialysis | 1.2 - 1.5 g/kg/day | Strict (<1 L/d) |
- | CRRT (CVVH/D/HDF) | Critical Illness / Sepsis| 1.5 - 2.5 g/kg/day | Liberal / None |
- +-----------------------------------------------------------------------------------------+
- 1. Conservative Management: Non-Dialyzed AKI
Obsolescence of Low-Protein Diets: Historically, clinicians prescribed low-protein or very-low-protein diets ( 0.4 to 0.6 g/kg/day 0.4\text{ to } 0.6\text{ g/kg/day} 0.4 to 0.6 g/kg/day ), such as the Giordano-Giovannetti regimen, to delay the initiation of dialysis by suppressing urea generation. In acute critical illness, this practice is obsolete and strictly contraindicated . Protein restriction fails to prevent dialytic intervention, accelerates negative nitrogen balance (losses often reach − 15 to − 25 g/day -15\text{ to } -25\text{ g/day} − 15 to − 25 g/day of nitrogen, representing 100 to 150 g/day 100\text{ to } 150\text{ g/day} 100 to 150 g/day of net lean muscle tissue loss), and significantly increases hospital mortality.
Modern Protein Targets:
Non-catabolic AKI: 0.8 to 1.0 g/kg/day 0.8\text{ to } 1.0\text{ g/kg/day} 0.8 to 1.0 g/kg/day (e.g., prerenal azotemia or resolving toxic nephropathy without systemic inflammation).
Catabolic / Critically Ill AKI: 1.2 to 1.5 g/kg/day 1.2\text{ to } 1.5\text{ g/kg/day} 1.2 to 1.5 g/kg/day . If uremia, hyperkalemia, or volume overload worsens under this regimen, renal replacement therapy should be initiated promptly rather than restricting dietary substrate.
Energy Requirements: 25 to 30 kcal/kg/day 25\text{ to } 30\text{ kcal/kg/day} 25 to 30 kcal/kg/day of actual dry weight or ideal body weight, or measured by indirect calorimetry.
Electrolytes & Fluid: Potassium, phosphorus, and magnesium must be tailored strictly to serum concentrations and residual urine output. In oliguric patients ( < 400 mL/day < 400\text{ mL/day} < 400 mL/day ), strict restriction of potassium ( < 2000 mg/day < 2000\text{ mg/day} < 2000 mg/day or < 1 mEq/kg/day < 1\text{ mEq/kg/day} < 1 mEq/kg/day ) and phosphorus ( < 800 to 1000 mg/day < 800\text{ to } 1000\text{ mg/day} < 800 to 1000 mg/day ) is required. In the post-oliguric diuretic phase, excessive urinary electrolyte dumping may mandate aggressive replacement.
2. Intermittent Hemodialysis (IHD)
Modality Profile: Hemodialysis utilizes high countercurrent dialysate flow rates ( 500 to 800 mL/min 500\text{ to } 800\text{ mL/min} 500 to 800 mL/min ) across a dialyzer membrane for brief durations ( 3 to 4 hours 3\text{ to } 4\text{ hours} 3 to 4 hours ), typically 3 to 4 times per week. Diffusion is the primary mechanism of solute clearance.
Nutrient Clearance: During each 3- to 4-hour hemodialysis treatment, approximately 10 to 12 g 10\text{ to } 12\text{ g} 10 to 12 g of free amino acids are washed out across the dialyzer membrane into the dialysate effluent. In addition, hemodialysis triggers a transient systemic inflammatory response and transiently increases whole-body proteolysis.
Protein Prescription: 1.2 to 1.5 g/kg/day 1.2\text{ to } 1.5\text{ g/kg/day} 1.2 to 1.5 g/kg/day to maintain neutral nitrogen balance and replace treatment-related amino acid losses.
Interdialytic Fluid & Volume Balance: Because IHD is intermittent, patients accumulate fluid between sessions. Interdialytic weight gain (IDWG) should not exceed 4 % to 5 % 4\%\text{ to } 5\% 4% to 5% of estimated dry weight (or < 1.5 to 2.0 kg < 1.5\text{ to } 2.0\text{ kg} < 1.5 to 2.0 kg ). Fluid intake is strictly limited to residual 24-hour urine output plus 500 to 1000 mL 500\text{ to } 1000\text{ mL} 500 to 1000 mL for insensible losses. Concentrated enteral formulas ( 1.5 to 2.0 kcal/mL 1.5\text{ to } 2.0\text{ kcal/mL} 1.5 to 2.0 kcal/mL ) with low electrolyte profiles are standard.
3. Continuous Renal Replacement Therapy (CRRT)
Modality Profiles: CRRT encompasses continuous veno-venous hemofiltration (CVVH, convective clearance), continuous veno-venous hemodialysis (CVVHD, diffusive clearance), and continuous veno-venous hemodiafiltration (CVVHDF, combined convective and diffusive clearance). Modern intensive care units utilize effluent flow rates of 20 to 35 mL/kg/hr 20\text{ to } 35\text{ mL/kg/hr} 20 to 35 mL/kg/hr .
Effluent Amino Acid Clearance: Because CRRT operates continuously 24 hours a day with highly permeable synthetic membranes, small-molecule solutes pass freely. Free amino acids have low molecular weights ( 75 to 204 Da 75\text{ to } 204\text{ Da} 75 to 204 Da ) and do not bind significantly to albumin; thus, their sieving coefficient ( S S S ) approaches 1.0 1.0 1.0 . Daily amino acid losses into the CRRT effluent range from 10 to 15 g/day 10\text{ to } 15\text{ g/day} 10 to 15 g/day , and can exceed 20 g/day 20\text{ g/day} 20 g/day during high-volume hemofiltration or severe systemic inflammation. This represents roughly 10 % to 15 % 10\%\text{ to } 15\% 10% to 15% of the total daily protein intake.
Protein Targets in CRRT: 1.5 to 2.5 g/kg/day 1.5\text{ to } 2.5\text{ g/kg/day} 1.5 to 2.5 g/kg/day . Nitrogen balance studies indicate that critically ill patients on CRRT require at least 1.5 to 1.8 g/kg/day 1.5\text{ to } 1.8\text{ g/kg/day} 1.5 to 1.8 g/kg/day merely to prevent severe negative nitrogen balance, while severely hypercatabolic, septic, or trauma patients may require up to 2.0 to 2.5 g/kg/day 2.0\text{ to } 2.5\text{ g/kg/day} 2.0 to 2.5 g/kg/day .
Fluid & Electrolyte Liberation: Because CRRT provides continuous, hourly ultrafiltration control, it eliminates volume restriction. Clinicians can infuse full-volume nutrition support, medications, and blood products without risking pulmonary edema. Furthermore, CRRT vigorously removes phosphorus, potassium, and magnesium. Hypophosphatemia occurs in 30 % to 50 % 30\%\text{ to } 50\% 30% to 50% of CRRT patients unless phosphorus is aggressively supplemented enterally, parenterally, or added directly to replacement fluids.
Non-Nutritional Caloric Contributions in CRRT
A critical competency tested in clinical practice is the identification and mathematical deduction of non-nutritional caloric intake generated by CRRT circuits. Failure to calculate these substrates leads directly to overfeeding, severe azotemia, hepatic steatosis, and respiratory failure. +-------------------------------------------------------------------------+
- | NON-NUTRITIONAL CALORIES IN THE CRRT CIRCUIT |
- +-------------------------------------------------------------------------+
- | Substrate Source | Metabolic Fate | Caloric Equivalent |
- | ---------------------- | ------------------------ | ------------------- |
- | Trisodium Citrate | Krebs (Citric Acid) Cycle| 3.0 kcal per gram |
- | (Anticoagulation) | Cleared by liver/muscle | (0.59 kcal per mmol)|
- | ---------------------- | ------------------------ | ------------------- |
- | Dextrose Dialysate / | Systemic uptake via | 3.4 kcal per gram |
- | Replacement Solutions | concentration gradient | monohydrate glucose |
- +-------------------------------------------------------------------------+
- 1. Regional Citrate Anticoagulation (RCA)
To prevent circuit clotting without the systemic bleeding risks of heparin, regional citrate anticoagulation is the preferred standard of care in CRRT:
Mechanism: Trisodium citrate is infused pre-filter into the arterial line of the circuit. Citrate chelates ionized calcium ( C a 2 + Ca^{2+} C a 2 + ), dropping circuit ionized calcium below 0.35 mmol/L 0.35\text{ mmol/L} 0.35 mmol/L , which completely arrests calcium-dependent steps of the coagulation cascade. A post-filter systemic infusion of calcium chloride or calcium gluconate restores physiological systemic ionized calcium ( 1.1 to 1.3 mmol/L 1.1\text{ to } 1.3\text{ mmol/L} 1.1 to 1.3 mmol/L ).
Systemic Metabolism: Approximately 40 % to 60 % 40\%\text{ to } 60\% 40% to 60% of the infused citrate-calcium complex is removed across the dialyzer/hemofilter into the effluent. The remaining 40 % to 60 % 40\%\text{ to } 60\% 40% to 60% enters the patient's systemic circulation, where each molecule of citrate is metabolized in the mitochondria of hepatocytes, renal tubular cells, and skeletal muscle via the citric acid (Krebs) cycle.
Caloric Value: Oxidation of citrate produces sodium bicarbonate and generates energy:
Citrate Energy Yield = 3.0 kcal per gram ( equivalent to 0.59 kcal per mmol ) \text{Citrate Energy Yield} = 3.0\text{ kcal per gram} \quad (\text{equivalent to } 0.59\text{ kcal per mmol}) Citrate Energy Yield = 3.0 kcal per gram ( equivalent to 0.59 kcal per mmol )
Clinical Caloric Load: Depending on blood flow rate, hematocrit, and effluent clearance, systemic citrate delivery typically supplies 200 to 800 kcal/day 200\text{ to } 800\text{ kcal/day} 200 to 800 kcal/day . In high-dose regional anticoagulation protocols, citrate intake may exceed 1000 kcal/day 1000\text{ kcal/day} 1000 kcal/day .
2. Dextrose Absorption from Dialysate & Replacement Fluids
Commercial CRRT fluids (dialysate and replacement fluids) often contain glucose at concentrations ranging from 100 to 110 mg/dL 100\text{ to } 110\text{ mg/dL} 100 to 110 mg/dL ( 5.5 to 6.1 mmol/L 5.5\text{ to } 6.1\text{ mmol/L} 5.5 to 6.1 mmol/L ), and some specialized peritoneal or dialysate fluids contain substantially higher concentrations:
When the dialysate glucose concentration exceeds the patient's blood glucose concentration, glucose diffuses down its concentration gradient across the membrane into the blood.
Net daily glucose absorption from CRRT dialysate/replacement solutions typically ranges from 100 to 500 kcal/day 100\text{ to } 500\text{ kcal/day} 100 to 500 kcal/day .
Mathematical Deduction Protocol
To avoid hypercapnia and hyperglycemia, clinicians must adjust the nutrition regimen:
Prescribed Nutrition Calories = Total Target Energy Expenditure − ( Citrate kcal + Dialysate Glucose kcal + Propofol/Dextrose Med kcal ) \text{Prescribed Nutrition Calories} = \text{Total Target Energy Expenditure} - (\text{Citrate kcal} + \text{Dialysate Glucose kcal} + \text{Propofol/Dextrose Med kcal}) Prescribed Nutrition Calories = Total Target Energy Expenditure − ( Citrate kcal + Dialysate Glucose kcal + Propofol/Dextrose Med kcal )
If a patient's total energy target is 1800 kcal/day 1800\text{ kcal/day} 1800 kcal/day , and they are receiving 450 kcal/day 450\text{ kcal/day} 450 kcal/day from citrate anticoagulation and 150 kcal/day 150\text{ kcal/day} 150 kcal/day from dialysate glucose absorption, the enteral or parenteral nutrition infusion must be formulated to deliver no more than 1200 kcal/day 1200\text{ kcal/day} 1200 kcal/day , while maintaining the full prescribed amino acid/protein target ( 1.5 – 2.5 g/kg/day 1.5\text{--}2.5\text{ g/kg/day} 1.5 – 2.5 g/kg/day ).
Micronutrient Management in Renal Disease
Micronutrient Non-Dialyzed AKI Intermittent Hemodialysis CRRT (Continuous Replacement)
Thiamine (Vitamin B1) Standard maintenance Supplement 100 mg/day 100\text{ mg/day} 100 mg/day Mandatory 100 mg/day 100\text{ mg/day} 100 mg/day ; continuous loss in effluent
Pyridoxine (Vitamin B6) Standard maintenance Supplement 5 – 10 mg/day 5\text{--}10\text{ mg/day} 5 – 10 mg/day Supplement 10 – 15 mg/day 10\text{--}15\text{ mg/day} 10 – 15 mg/day ; active clearance
Folate (Vitamin B9) Standard maintenance Supplement 1 mg/day 1\text{ mg/day} 1 mg/day Supplement 1 mg/day 1\text{ mg/day} 1 mg/day ; dialyzed out
Vitamin C (Ascorbic Acid) Avoid high doses Max 100 – 200 mg/day 100\text{--}200\text{ mg/day} 100 – 200 mg/day Max 100 – 200 mg/day 100\text{--}200\text{ mg/day} 100 – 200 mg/day ; avoid secondary oxalosis
Fat-Soluble Vitamins (A, E, K) Avoid excess Vitamin A Avoid excess Vitamin A Avoid excess Vitamin A; risk of hypervitaminosis A
Zinc & Selenium Monitor levels Standard replacement Supplement; substantial losses bound to effluent amino acids
Oxalosis Risk with Vitamin C: Ascorbic acid is metabolized to oxalate. In renal impairment, excessive vitamin C supplementation ( > 200 mg/day > 200\text{ mg/day} > 200 mg/day ) leads to systemic calcium oxalate crystal deposition in renal tubules, myocardium, and vasculature ( secondary systemic oxalosis ). Dosing should never exceed 100 to 200 mg/day 100\text{ to } 200\text{ mg/day} 100 to 200 mg/day .
Hypervitaminosis A Risk: Retinol-binding protein (RBP) is normally catabolized by renal proximal tubular cells. In renal failure, RBP accumulates, raising circulating free retinol to toxic levels. Routine vitamin A supplementation should be minimized or omitted in acute and end-stage renal failure.